Literature DB >> 20490738

Stepwise positive association between APOA5 minor allele frequencies and increasing plasma triglyceride quartiles in random patients with hypertriglyceridemia of unclarified origin.

Ferenc Hadarits1, Péter Kisfali, Márton Mohás, Anita Maász, Katalin Sümegi, Melinda Szabó, Katalin Hetyésy, Andrea Valasek, Ingrid Janicsek, István Wittmann, Béla Melegh.   

Abstract

Apolipoprotein A5 (ApoA5) gene and its protein product play a central role in the complex regulation of circulating triglyceride levels in humans. Naturally occurring variants of the apolipoprotein A5 gene have been associated with increased triglyceride levels and have been found to confer risk for cardiovascular diseases. In our study, four polymorphisms, the T-1131C, IVS3+G476A, T1259C, and C56G alleles of APOA5 were analyzed in a total of 436 patients by polymerase chain reaction-restriction fragment length polymorphism methods. The randomly selected patients were classified into four quartile (q) groups based on triglyceride levels (q1: TG<1.31 mmol/l; q2: 1.31-2.90 mmol/l; q3: 2.91-4.85 mmol/l; q4: TG>4.85 mmol/l). We observed significant stepwise increasing association between the four APOA5 minor allele carrier frequencies and plasma triglyceride quartiles: -1131C (q1: 4.44%; q2: 8.95%; q3: 12.9%; q4: 20.6%), IVS3 + 476A (q1: 4.44%; q2: 5.79%; q3: 11.1%; q4: 19.7%), 1259C (q1: 4.44%; q2: 6.84%; q3: 11.1%; q4: 20.6%) and 56G (q1: 5.64%; q2: 6.31%; q3: 11.16%; q4: 11.9%). The serum total cholesterol and high density lipoprotein-cholesterol levels also showed allele-dependent differences in the quartiles. The findings presented here revealed a special arrangement of APOA5 minor alleles in patients with different serum triglyceride ranges in Hungarians.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20490738     DOI: 10.1007/s12253-010-9273-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  30 in total

1.  Combining carotid intima-media thickness with carotid plaque on screening for coronary heart disease.

Authors:  David S Wald; Jonathan P Bestwick; Geraint Morton; Linda Drummond; Nick Jenkins; Pouran Khodabakhsh; Nick P Curzen
Journal:  J Med Screen       Date:  2009       Impact factor: 2.136

2.  Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants.

Authors:  Kasuen Wong-Mauldin; Vincent Raussens; Trudy M Forte; Robert O Ryan
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

3.  Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration.

Authors:  H N van der Vliet; M G Sammels; A C Leegwater; J H Levels; P H Reitsma; W Boers; R A Chamuleau
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

4.  Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome.

Authors:  P Kisfali; M Mohás; A Maász; N Polgár; F Hadarits; L Markó; P Brasnyó; K Horvatovich; T Oroszlán; Z Bagosi; Z Bujtor; B Gasztonyi; J Rinfel; I Wittmann; B Melegh
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-08-18       Impact factor: 4.222

5.  Relation between coronary artery disease, risk factors and intima-media thickness of carotid artery, arterial distensibility, and stiffness index.

Authors:  Sait Alan; Mehmet S Ulgen; Onder Ozturk; Bircan Alan; Levent Ozdemir; Nizamettin Toprak
Journal:  Angiology       Date:  2003 May-Jun       Impact factor: 3.619

6.  Obesity, hyperlipidemia, and metabolic syndrome.

Authors:  Michael Charlton
Journal:  Liver Transpl       Date:  2009-11       Impact factor: 5.799

7.  Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease.

Authors:  Csaba Szalai; Márton Keszei; Jenõ Duba; Zoltán Prohászka; Gergely Tibor Kozma; Albert Császár; Sándor Balogh; Zsuzsa Almássy; George Fust; Antal Czinner
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

8.  Lipoprotein lipase activity determined in vivo is lower in carriers of apolipoprotein A-V gene variants 19W and -1131C.

Authors:  J Kovář; V Adámková
Journal:  Physiol Res       Date:  2007-07-26       Impact factor: 1.881

9.  Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease.

Authors:  Julie St-Pierre; Isabelle Lemieux; Marie-Claude Vohl; Patrice Perron; Gérald Tremblay; Jean-Pierre Després; Daniel Gaudet
Journal:  Am J Cardiol       Date:  2002-07-01       Impact factor: 2.778

10.  Endothelial dysfunction, carotid artery plaque burden, and conventional exercise-induced myocardial ischemia as predictors of coronary artery disease prognosis.

Authors:  Bonpei Takase; Yoshihiro Matsushima; Akimi Uehata; Masayuki Ishihara; Akira Kurita
Journal:  Cardiovasc Ultrasound       Date:  2008-12-16       Impact factor: 2.062

View more
  1 in total

1.  Common functional variants of APOA5 and GCKR accumulate gradually in association with triglyceride increase in metabolic syndrome patients.

Authors:  Ferenc Hadarits; Péter Kisfali; Márton Mohás; Anita Maász; Balázs Duga; Ingrid Janicsek; István Wittmann; Béla Melegh
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.